|Home | About | Journals | Submit | Contact Us | Français|
With the causes of perinatal brain injuries still unclear and the probable role of hemodynamic instability in their etiology, bedside monitoring of neonatal cerebral hemodynamics with standard values as a function of age are needed. In this study, we combined quantitative frequency domain near infrared spectroscopy (FD-NIRS) measures of cerebral tissue oxygenation (StO2) and cerebral blood volume (CBV) with diffusion correlation spectroscopy (DCS) measures of a cerebral blood flow index (CBFix) to test the validity of the CBV-CBF relationship in premature neonates and to estimate cerebral metabolic rate of oxygen (rCMRO2) with or without the CBFix measurement. We measured 11 premature neonates (28–34 weeks gestational age) without known neurological issues, once a week from one to six weeks of age. In nine patients, cerebral blood velocities from the middle cerebral artery were collected by transcranial Doppler (TCD) and compared with DCS values. Results show a steady decrease in StO2 during the first six weeks of life while CBV remains stable, and a steady increase in CBFix. rCMRO2 estimated from FD-NIRS remains constant but shows wide interindividual variability. rCMRO2 calculated from FD-NIRS and DCS combined increased by 40% during the first six weeks of life with reduced interindividual variability. TCD and DCS values are positively correlated. In conclusion, FD-NIRS combined with DCS offers a safe and quantitative bedside method to assess CBV, StO2, CBF, and rCMRO2 in the premature brain, facilitating individual follow-up and comparison among patients. A stable CBV-CBF relationship may not be valid for premature neonates.
Because of the expansion of neonatal intensive care and assisted reproductive technology, a significant and increasing number of neonates are born prematurely [Martin et al., 2009]. These patients are at special risk for cerebral injuries such as hypoxia-ischemia, stroke, and periventricular leukomalacia, any of which can be associated with long-term epilepsy or neurological deficits [Kiechl-Kohlendorfer et al., 2009]. With the cause of these disorders still unclear and the probable role of hemodynamic instability in their etiology, it is essential to develop bedside methods to monitor cerebral hemodynamic variables. Although the emphasis has been on supportive care [Perlman, 2006], there is an increasing effort to organize clinical trials and test new agents [Marret et al., 2008]. However, there are very few tools available for routine bedside assessment of neonatal brain health, and they do not assess local cerebral hemodynamics. While amplitude-integrated electroencephalography (aEEG), head ultrasound (US), and transcranial Doppler (TCD) remain the most common bedside methods, the value of aEEG is still unclear [Shellhaas et al., 2007], US is notoriously insensitive to brain injury [Blankenberg et al., 2000], and TCD estimates blood flow only in the main arteries.
Our current understanding of metabolic and vascular regional brain development in infants is derived from positron emission tomography (PET), single photon emission computed tomography (SPECT), and functional magnetic resonance imaging (fMRI) studies. Using 18F-FDG PET, a correlation has been established between glucose utilization and behavioral and neurophysiological maturation [Chugani and Phelps, 1986]. In neonates, glucose uptake is highest in the sensorimotor cortex, with generally low functional activity over most of the other regions. During the second and third months of life, glucose uptake begins to increase in the parietal, temporal and primary visual cortices, coinciding with improvements in motor and visual skills [Amiel-Tison and Grenier, 1986; Bayley, 1993] as well as with changes in the EEG response to stimuli [Kellaway, 2003]. Other investigators have observed similar developmental changes in cerebral blood flow (CBF) using H215O PET [Altman et al., 1988] and 123I-IMP SPECT [Tokumaru et al., 1999]. Regional myelination changes also correlate with glucose uptake and increases in CBF [Peterson et al., 2003], suggesting either higher energy demand during myelination or, more likely, increased cerebral activity in myelinating regions. However, these techniques are rarely performed because they cannot be used at the bedside, and PET and SPECT present a risk of radiation exposure.
There have been a few previous reports of cerebral metabolic rate of oxygen (CMRO2) in neonates; CMRO2 was reported higher in term neonates compared to premature neonates [Altman et al., 1988; Elwell et al., 2005; Skov et al., 1993; Yoxall and Weindling, 1998]. However, these studies had small samples of subjects with injuries such as hyaline membrane disease or intraventricular hemorrhage in the premature population and suspicion of hypoxic ischemic injury in the term infants.
To better understand normal hemodynamic development and to promptly identify pathological development, a safe portable technique for quantitative, reliable monitoring of local cerebral blood volume (CBV), cerebral blood flow, oxygen saturation (StO2), and CMRO2 is needed.
Near infrared spectroscopy (NIRS) provides bedside monitoring of CBV and StO2. It is portable, noninvasive and safe because it uses nonionizing radiation and emits less energy than a head ultrasound [Bozkurt and Onaral, 2004; Ito et al., 2000]. For this reason, NIRS is particularly adapted for use in neonates and infants, and was first applied to the study of the neonatal brain in the mid-1980s [Benaron et al., 1992; Brazy et al., 1985; Wyatt et al., 1986]. Continuous wave near infrared spectroscopy (CW-NIRS) has now become a widespread noninvasive measure of oxy- and deoxy-hemoglobin concentrations (HbO and HbR) [Carlsson et al., 2008; Watanabe et al., 2008; Zaramella et al., 2007]. However, it does not allow absolute measurements.
There have been attempts to optically measure regional CBF in neonates using NIRS, but either oxy-hemoglobin was used as a tracer [Edwards et al., 1988; Elwell et al., 2005; Meek et al., 1998; Noone et al., 2003], a method applicable only on ventilated infants, or indocyanine green was used as a tracer [Patel et al., 1998], with the injection of the dye not performed in healthy infants for ethical reasons.
The absence of absolute hemoglobin concentration and oxygenation measurements and of reliable CBF assessment has been a major obstacle to the successful clinical application of NIRS. The lack of quantification prevents estimation of standard values and efficient comparison of at-risk neonates with normal neonates [Nicklin et al., 2003].
Advances have been made to address the issue of absolute measurements by using time-domain and frequency-domain spectroscopy (TD-NIRS and FD-NIRS, respectively), both of which allow absolute quantification of StO2 and CBV [Fantini et al., 1995; Hamaoka et al., 2000]. Although TD-NIRS has had limited clinical use so far because of instrument complexity [Benaron et al., 1994; Hebden et al., 2002], the development of FD-NIRS systems has increased quantitative accuracy while maintaining simplicity [Ijichi et al., 2005; Zhao et al., 2005]. Recently, FD-NIRS has been used successfully to measure the evolution of CBV, StO2, and CMRO2 over the first year of normal brain development [Franceschini et al., 2007].
Regarding CBF, a recently developed method of diffuse correlation spectroscopy (DCS) provides a measure of tissue perfusion based on the movement of scatterers (i.e., blood cells) inside the tissue [Boas and Yodh, 1997; Cheung et al., 2001]. It has proven a valid assessment of CBF changes in the brain [Durduran et al., 2004b; Li et al., 2005].
In this study our aims were to (1) establish standard baseline values of CBV and StO2 and their evolution during the first six weeks of life in premature neonates with neither brain injury nor severe cardiovascular issues, (2) evaluate the relevance of DCS for baseline CBF assessment in neonates, and (3) determine whether CMRO2 changes could be better assessed with combined FD-NIRS and DCS rather than a hypothetical CBV-CBF relationship [Grubb et al., 1974].
We recruited from the NICU or the Well Baby Nursery at the Massachusetts General Hospital (MGH) 11 premature neonates, 28 to 34.5 weeks gestational age (wGA), with no clinical suspicion of brain injury (Table I). All of them had APGAR scores between 7 and 9 after 5 min. For this initial study, some subjects requiring respiratory support but with normal arterial saturation were included (see Supporting Information table online for detailed clinical information). We measured each baby once a week from one to six weeks of age (ages in days were rounded off to the nearest week). Our Institutional Review Board approved the study and parents signed an informed consent.
For frequency-domain near infrared spectroscopy, we used a customized commercial frequency-domain oximeter from ISS Inc., Champaign, IL, USA. It has 16 laser sources, emitting at eight wavelengths with two redundant pairs (659, 2 × 685, 755, 778, 798, and 2 × 825 nm) and two PMT detectors (http://www.iss.com/products/oxiplex/). The sources were modulated at 110 MHz; the detectors at 110 MHz plus 5 kHz to achieve heterodyne detection. The lasers were rapidly multiplexed in sequence, so only one source was on at any given time (for 10 ms), allowing separation by software on the detector side.
For diffuse correlation spectroscopy, we used a custom-built instrument similar to the system developed by Drs. Arjun Yodh and Turgut Durduran at the University of Pennsylvania [Cheung et al., 2001; Durduran et al., 2004b; Li et al., 2005]. It consists of one long coherence length laser source at 785 nm (CrystaLaser, Reno, NV, USA) and four photon-counting avalanche photodiodes (APD) as detectors (Perkin-Elmer, Quebec, Canada). The individual counting signals were converted to temporal intensity auto-correlation functions by an eight-channel correlator (http://www.correlator.com/).
Both instruments were compact enough to be moved on a small cart to the infant’s bedside in the hospital. They were controlled by the same laptop and operated in sequence.
Two groups of eight NIRS lasers (~ 1 mW power each) were combined into two source fiber bundle, and each detector coupled to a fiber bundle. The NIRS fiber bundles (each 2.5 mm diameter) were arranged in a row in a black rubber probe (5 × 2 × 0.5 cm3) with source-detector distances of 1, 1.5, 2, and 2.5 cm (Fig. 1C). Multiple distances are necessary to quantify absorption and scattering coefficients with this system [Fantini et al., 1995]. Because we separately measured absorption and scattering there was no need to assume a path length factor at each wavelength as is done with CW systems. The source-detector separations we chose (from 1 to 2.5 cm) are adequate for a depth penetration of about 1 cm, which includes the cerebral cortex in neonates [Fabbri et al., 2004; Franceschini et al., 1998].
The DCS laser (50 mW power) was coupled to a multimode optical fiber (62.5 μm diameter) and diffused at the fiber tip to a 3-mm spot; the DCS detectors were coupled to 5.6 μm diameter optical fibers which achieved single mode operation at 785 nm. The fibers were arranged in a second row parallel to the NIRS bundles, with the same source-detector separations (Fig. 1C). For this paper, only the 1.5 cm pair was used in the results, because it was the largest distance that provided a good signal-to-noise ratio in all babies.
FD-NIRS and DCS were performed in turn at bedside (Fig. 1A). For both, measurements were obtained from up to seven areas of the head (Fp1, FpZ, Fp2, T3, T4, CP3, and CP4, according to the 10–20 system, Fig. 1B). The optical probe was held in each location for 8 s of data acquisition. Measurements with each instrument were repeated up to three times in each location, with the probe repositioned in order to make up for local inhomogeneities such as hair and superficial large vessels and thus ensure that the measurement was representative of the underlying brain region. The total number of positions and repetitions depended on the cooperation of the subject and the presence of other medical devices on the head. Total examination time was ~45 min. Hemoglobin counts were taken from clinical reports and SaO2 was obtained from monitoring devices.
To validate DCS measurements, we collected TCD measurements of cerebral blood velocities (PS, peak systolic; ED, end diastolic) for the middle cerebral artery, which were acquired for clinical reasons in nine patients within a day of our DCS measurement. We then compared them with DCS values. Among these patients, six were participants in the main study (patients 4, 5, 6, 7, 10, and 11); each provided several DCS-TCD time points. The remaining three patients had only one DCS measurement, and for that reason were not part of the longitudinal optical study. These three infants were also stable premature neonates without brain injury (see Table I); each provided one DCS-TCD time point.
We used the amplitude and phase data collected at each wavelength to determine average absorption and scattering coefficients using the multi-distance frequency-domain method [Fantini et al., 1995].
To analyze the FD-NIRS data in a standardized fashion we developed an automated data analysis routine, which includes data quality assessment and data rejection based on previously established statistical criteria. In particular we used the following procedure:
For each wavelength we discarded all data points with R2 < 0.97 for the fit of the raw optical data (amplitude and phase) to the light transportation model; if more than 80% of data points were discarded, all data for that wavelength were discarded; if more than two wavelengths had to be discarded, one source-detector distance was discarded and the data point and wavelength selection steps were repeated; if more than one distance had to be discarded, the whole measurement was discarded. In addition, the whole measurement was discarded if P > 0.02 for the fit of the absorption coefficients with the hemoglobin spectra or for a linear fit of the reduced scattering coefficient versus wavelength. Using these objective rejection criteria, we were able to discard data affected by hair, bad coupling to the head, bending of the probe, and motion artifacts, and thus retain only the highest quality data for further analysis.
We derived HbO and HbR by fitting the absorption coefficient at our wavelengths with the hemoglobin spectra using the extinction coefficients reported in the literature [Wray et al., 1988] and a 75% concentration of water [Wolthuis et al., 2001], and from them calculated total hemoglobin concentration HbT (μMol) and StO2:
CBV was calculated using the following equation [Takahashi et al., 1999]:
where CBV is in ml/100 g, HbT is in μMol, MWHb (64,500 g/Mol) is the molecular weight of hemoglobin, Dbt (1.05 g/ml) is the brain tissue density [Kretschmann et al., 1986] and HGB (g/dl) is hemoglobin concentration in the blood. For 20% of measurements HGB was not available in clinical charts, in which case standard normal values for HGB for age were used [de Alarcón and Werner, 2005; Wolff and Goodfellow, 1955]. Uncertainties in the above physiologic parameters have previously been reported [Franceschini et al., 2007].
To estimate relative CMRO2 (rCMRO2) from FD-NIRS only, we used the relation
where SaO2 is the arterial and SvO2 the venous hemoglobin oxygenation.
We worked from the assumption that:
StO2 = aSaO2 + bSvO2, with a + b = 1 [Watzman et al., 2000] and a and b are constants.
Next we assumed a constant power law relation between changes in CBF and CBV
Finally, we obtained
rCMRO2 was calculated as the ratio between the subject’s values and the average of all subjects’ first week values.
Because the reference values are the average of all subjects’ first week values, and not the subject’s own first week value, the initial average of all subjects is not exactly one.
In each infant for each measurement session, multiple measurements in the same location were averaged together, and for this article results were averaged over all positions. We verified that results are reliable when only one location is considered by comparing results using only frontal or only parietal measurements, which did not produce significant differences.
Diffuse correlation spectroscopy offers a measure of tissue perfusion that depends on both the movement of scatterers inside the tissue and the tissue optical properties [Boas and Yodh, 1997; Cheung et al., 2001]. To maximize accuracy we calculated the actual optical absorption and scattering coefficients at 785 nm by interpolating from the FD-NIRS measurements.
DCS data comprise a set of intensity auto-correlation curves (over a delay time range of 200 ns ~1s in our case) acquired sequentially, about once per second. The diffusion correlation equation offers the theoretical framework for analyzing our data. As detailed in [Boas et al., 1995; Boas and Yodh, 1997] and further validated in [Cheung et al., 2001; Culver et al., 2003; Durduran et al., 2004a; Durduran et al., 2005] the normalized intensity temporal auto-correlation function, g2(τ), is given by:
where the source is at position rs, the detector is at position rd, the correlation time is τ, the reduced scattering coefficient is μs′, the absorption coefficient is μa, the wave number for the laser light is ko, Δr2(τ) is the mean square displacement of the moving scattering particles (i.e., the red blood cells) where … indicates an ensemble average, and PRBC is the probability of scattering from a moving red blood cell instead of the static tissue matrix. The most common model for the mean square displacement of the moving particles is Brownian motion:
where DB is the Brownian diffusion coefficient. Since PRBC is generally unknown, the two parameters are usually grouped together (DBPRBC) to form a blood flow index hereafter referred to as CBFix, which has been shown to follow tissue perfusion quite accurately [Yu et al., 2005].
To obtain the blood flow index, we fit Eq. (7) to the measured temporal auto-correlation functions, and, as we did in analyzing the FD-NIRS data, we reject measurements that do not met the objective criteria described below in order to maintain good data quality.
First, we discarded correlation curves for which the tail (large τ) of the fitting curve differed from 1 by more than 0.02, the cumulative variation among the 3 first points of the curve was more than 0.1, or the average value of the 3 first points of the curve was more than 1.6 (all indicative of high measurement noise, as a g2(τ) curve obtained using randomly polarized light reaches a maximum of 1.5 at τ = 0 and decays to 1 for large τ values [Kirkpatrick et al., 2008]). If more than 50% of curves were discarded, the whole set was discarded. Finally, we used only sets for which the fit values from the kept curves had a coefficient of variation (COV, standard deviation/mean ratio) <15%.
Although measurements of relative changes in blood flow index have previously been reported, for example during functional measurements [Durduran et al., 2004b] or cancer therapy monitoring [Zhou et al., 2007], the present work is one of the first attempts to use DCS to obtain absolute blood flow index measurements. As described by Yu et al.  the DCS blood flow index is proportional to tissue perfusion. To compare measurements taken at different locations, times, and subjects, we made the assumption that the proportionality factor is constant within location, ages, and subjects.
We assessed the reproducibility of the DCS measurements by calculating the COV for a set of 10 measurements on a 1% intralipid liquid phantom using the probe described above. COV was 12%. We then ran the same calculation for each set of three measurements in each location for every subject included in this study. This intralocation COV was 13 ± 2%. We believe the slightly larger COV in vivo is because of the fact that we do not reposition the probe exactly in the same location, but rather in a slightly different area, to obtain an average value at that head location. Inhomogeneities in the underlying vasculature may be responsible for the higher COV of CBFix in vivo. For comparison, the error we obtain with FD-NIRS is 11 ± 1% for HbT and 4 ± 1% for StO2. These errors are significantly smaller than the changes of StO2, CBFix, and rCMRO2 with age (see Results).
As for NIRS, in each infant for each measurement session DCS measurements in the same location were averaged together, and for this article results were averaged over all positions.
To estimate relative CMRO2 (rCMRO2) from combined DCS and FD-NIRS measures, without assuming a CBV-CBF relationship [Eq. (5)], we used the relation:
We used Matlab® (http://www.mathworks.com/products/matlab/) for all data processing, Excel® (http://office.microsoft.com/en-us/excel/) for plotting and Statistica® (http://www.statsoft.com/) for regressions and statistics.
In Figure 2 we plot individual traces of HbT, CBV, StO2, CBFix, rCMRO2 estimated from FD-NIRS only, and rCMRO2 calculated by combining FD-NIRS and DCS as a function of age. We plot averages ±95% confidence intervals of these variables as a function of age in Figure 3. Because we had 11 subjects, the confidence intervals were calculated using Student’s t table for small samples. For each average variable, we calculated and plotted the linear regression, with R2 and P-value.
Individual traces of HbT show a decrease during the first six weeks of life (Fig. 2A). The average HbT significantly decreases from 40 ± 7 to 28 ± 5 μM during this period (31% decrease, R2 = 0.93, P-value = 0.002) (Fig. 3A).
Individual traces of StO2 show a consistent decrease during the first six weeks of life (Fig. 2B). The average StO2 significantly decreases from 73 ± 4% to 57 ± 4% during this period (21% decrease, R2 = 0.98, P-value <0.001) (Fig. 3B).
In the contrary, individual traces of CBV do not show a consistent pattern of evolution across subjects during the first six weeks of life (Fig. 2C). The average CBV stays constant around 1.7 ± 0.3 ml/100 g during this period (R2 = 0.06, P-value = 0.65) (Fig. 3C). This is consistent with previously reported values [Leung et al., 2004].
Individual traces of CBFix calculated from DCS show a consistent increase during the first six weeks of life (Fig. 2D). The average CBFix significantly increases from 3.3 ± 0.4 to 4.6 ± 0.3 during this period (28% increase, R2 = 0.84, P-value = 0.001) (Fig. 3D).
Individual rCMRO2 traces estimated from FD-NIRS alone do not show a consistent pattern of evolution across subjects during the first six weeks of life (Fig. 2E). On an average, rCMRO2 estimated from FD-NIRS alone remains constant during this period 1.0 ± 0.4 (R2 = 0.13, P-value = 0.48) and shows a large variation among subjects (average standard deviation = 0.52) (Fig. 3E).
Individual rCMRO2 traces calculated by combining FD-NIRS and DCS show instead a strong increase with age during the first six weeks of life (Fig. 2F). On average, rCMRO2 calculated by combining FD-NIRS and DCS increases from 0.9 ± 0.3 to 1.5 ± 0.2 (40% increase, R2 = 0.95, P-value <0.001), and there is a much smaller variation between subjects than when using FD-NIRS alone (average standard deviation = 0.24) (Fig. 3F).
HbT and StO2 seemed higher in neonates born after 32 wGA compared with neonates born before 31 wGA, for the first four weeks of life (data were missing for weeks 5 and 6 in the first group) (Fig. 2A,B). However, our small samples did not allow for statistics on this effect.
To validate the DCS measures of CBF, we plotted the average of PS and ED values from the TCD versus CBFix from the DCS in Figure 4. We also calculated and plotted the linear regression, with R2 and P-value. This shows that DCS measurements are positively correlated (R2 = 0.28, P-value = 0.04) with TCD measurements.
This study shows that (1) during the first six weeks of life of premature neonates, HbT and StO2 decrease while CBV stays stable, and CBF increases, (2) DCS appears a valid technique to measure an index of baseline CBF in neonates, (3) rCMRO2 seems better estimated by combining FD-NIRS and DCS than by assuming a CBV-CBF relationship, questioning the validity of assuming a constant relationship in this population. Because of the reduced variance, only by using the blood flow measure are we able to see increases in CMRO2 during the first six weeks of life.
Our data provide initial quantitative values for the optical hemodynamic assessment of premature neonates during the first six weeks of life, and support the relevance of DCS absolute measures of CBF index along with FD-NIRS for in vivo studies of the neonatal brain.
The stability of CBV and decrease of HbT and StO2 during the first six weeks of life is consistent with previous results in healthy term and preterm neonates using the same technique during the first six to eight weeks of life [Franceschini et al., 2007]. We believe the decrease in StO2 (21%) and HbT (31%) are due to the 29% decrease in HGB in our subjects during the same period. This is consistent with the decrease in hematocrit observed during the transition from fetal hemoglobin to adult hemoglobin occurring six to eight weeks after birth [Oski and Naiman, 1982]. The constant CBV suggests that during that period vessels do not dilate to increase volume despite the decrease in red blood cells and oxygen delivery arising from decreased hematocrit.
Additionally, we measured an increase in CBFix of about 28% during the first six weeks of life, which is consistent with TCD studies of term and premature healthy neonates [Kehrer et al., 2005], basal cerebral artery flow velocity measurements during the first 20 days of life [Bode and Wais, 1988], and SPECT measurements of neonates and infants with transient neurological events [Tokumaru et al., 1999]. This CBF increase may be an attempt to maintain appropriate brain oxygenation despite the HGB decrease. Indeed, while measured HGB and HbT decrease by 29% and 31%, respectively, during the first six weeks of life, StO2 decreases only by 21%.
Moreover, the blood flow increase may result from the fact that a decreased HGB and hematocrit reduce blood viscosity and resistance, causing the flow to increase under constant pressure. In microvessels the hematocrit is lower than the measured value in large vessels [Lipowsky et al., 1980]. Assuming an initial hematocrit of 40 in these micro-vessels and using the values reported in [Pries et al., 1992] for vessel diameters between 50 and 200 μm, a 29% reduction in hematocrit causes a reduction in viscosity of 23–25% and an increase in blood flow of 29–33%. This is close to the 28% increase in CBFix reported in this article.
The correlation between DCS and TCD measurements shows that DCS is a valid technique to measure an index of baseline CBF in neonates. However the correlation was moderate (R2 = 0.28), even when we tried normalizing CBFix by the amount of blood cells in tissues for each subject (as blood cells are the main moving scatterer responsible for the DCS signal). This moderate R2 between TCD and DCS is also reported by [Buckley et al., 2009]. DCS and TCD have different sensitivity mechanisms: TCD is representative of a large artery flow, while DCS is weighted toward smaller vessels because of their higher volume density. Overall, further assessment of DCS is necessary, for example by using absolute Arterial Spin Labeling Magnetic Resonance Imaging (ASL-MRI) measurements.
The interindividual variance of rCMRO2 is far less when combining DCS with NIRS than when using only NIRS and assuming a CBV-CBF relationship with constant β. Considering that our NIRS assessments of HbT and StO2 evolution during the first six weeks of life are stable across subjects, that these measurements’ reproducibility is 11 ± 1% and 4 ± 1%, respectively, and that the same absorption coefficients used to calculate CBV are also used to calculate CBFix, it is unlikely that this difference comes from an invalid CBV measure. Instead, these results suggest the CBF-CBV relationship may not be valid in premature neonates.
The increase in rCMRO2 resulting from using DCS measures of CBFix is consistent with electrophysiology showing increasing neuronal activity [Lamblin et al., 1999] and with PET studies showing increasing cortical glucose uptake during the same period [Chugani, 1998; Chugani and Phelps, 1986].
Using Eq. (5) with our values of CBV and CBFix for all measurements in all subjects, we calculated the average value of β with the assumption of a constant CBV-CBF relationship during this period. This calculation gives β = 0.9 ± 1.1, which is not physiologically viable as the minimum value of β is set at 2 by the Poiseuille’s Law for laminar flow at fixed pressure (Poiseuille, 1840). This discrepancy in β would be expected if flow changes are arising from reduced vascular resistance due to hematocrit decreases rather than volume increases.
In this study we averaged results from all locations. Because there may be a difference in the pattern of hemodynamic variables among different locations [Chugani and Phelps, 1986; Franceschini et al., 2007], we carried out the same analysis using only frontal, parietal, or temporal recordings. The results did not show any difference between these different locations, justifying averaging them for this study.
We also tested whether averaging data by corrected gestational age (cGA) instead of age would change the patterns of evolution of the variables. Except for a larger interindividual variability for all variables the patterns were similar, suggesting that age is a better predictor of these variables than cGA among our population.
The values of HbT and StO2 seemed higher in subjects born after 32 wGA, but that difference did not reach significance. Further research involving larger samples is required to investigate this effect.
Because premature neonates without any medication or respiratory assistance were few, we had to recruit some patients under treatment. Caffeine is known to increase neural stimulation and decrease CBF, uncoupling CBF and rCMRO2, but its effects on baseline CBV, StO2 and rCMRO2 remain controversial [Chen and Parrish, 2009; Perthen et al., 2008]. Ventilation modes are also suspected to affect brain hemodynamics, although results are still inconsistent [Milan et al., 2009]. It is unclear how these parameters influenced our data, but as this study is part of a larger prospective study where any neonate in the hospital is eligible for recruitment, we may be able to address these issues in future publications.
FD-NIRS combined with DCS offers a safe, highly effective, and quantitative bedside method to track CBV, StO2, and CBF as well as rCMRO2 in the premature brain. Quantitative values facilitate individual follow-up and comparison among patients. Using DCS measures of CBF instead of CBF estimates based on adult data of the CBV-CBF relationship reduced variation, suggesting that stable adult values of CBV-CBF relationship may not be accurate in the premature brain.
The ability to safely and routinely monitor premature neonates for regional cerebral development of oxygen utilization, cerebral blood volume (i.e., vascularization) and cerebral blood flow at bedside is of clinical importance as it may allow early detection of abnormal hemodynamics. It is now essential to determine if DCS can also detect brain injuries in infants, as suggested by recent results in the piglet brain [Zhou et al., 2009]. It could then be associated with NIRS detection of brain injury using CBV and rCMRO2 [Grant et al., 2009]. These studies are being planned, as are studies correlating these quantitative NIRS variables with long-term cognitive and behavioral outcomes to determine if they are useful predictors.
The authors thank all the families for their participation in this study and the nurses, physicians, and staff in the Neonatal ICU, the Special Care Nursery, Pediatric Neurology, and the maternity units at Massachusetts General Hospital for helping with recruitment and data collection.
Contract grant sponsor: NIH; Contract grant number: R01 HD42908.
Additional Supporting Information may be found in the online version of this article.